Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
radiolabeled epratuzumab · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| radiolabeled epratuzumab | DRUG | - |
Inclusion: * Histological or cytological diagnosis of B-cell lymphoma, and has failed at least one regimen of standard chemotherapy. (All histological grades of NHL will be eligible for this trial.) * Measureable via CT, with at least one lesion \> or = 1.5cm in one or both dimensions. (Splenic tum...
Radiolabeled epratuzumab is an investigational small molecule being studied for the treatment of Non-Hodgkin's Lymphoma. It is a radiolabeled form of the antibody epratuzumab, designed to deliver radiation directly to cancer cells. As of the available data, it remains in clinical development and is not approved for any indication.
Radiolabeled epratuzumab is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with Non-Hodgkin's Lymphoma.
Radiolabeled epratuzumab is in Phase 1 clinical development. A Phase 1 trial has been completed, and there are no active trials currently listed. The drug is investigational and has not received FDA approval for any use.
Radiolabeled epratuzumab has been studied in one completed Phase 1 clinical trial with the identifier NCT00061425, titled "Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG." The trial enrolled adult patients with Non-Hodgkin's Lymphoma or B-Cell Lymphoma and was not randomized or blinded.
Radiolabeled epratuzumab is a radiolabeled form of the antibody epratuzumab, meaning it is epratuzumab attached to a radioactive isotope, such as Yttrium-90. This modification allows the drug to deliver targeted radiation to cancer cells. The radiolabeled version is being studied specifically for Non-Hodgkin's Lymphoma.